Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Adimab raises $6.2mm in Series A round

Executive Summary

Adimab (yeast-derived antibodies) raised $6.2mm in a Series A round co-led by SV Life Sciences and Polaris Venture Partners. Nonprofit organization Angeli Parvi, which provides seed financing to Dartmouth College entrepreneurial ventures, also participated. Partners from Polaris and SV Life Sciences joined Adimab's board.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies